Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for protein clues in common eye diseases

NCT ID NCT07500324

Knowledge-focused Sponsor: Fondazione G.B. Bietti, IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study collects fluid and blood samples from 260 people with age-related macular degeneration, diabetic retinopathy, or retinal detachment, plus healthy controls. Researchers will analyze proteins in these samples to identify markers that could help diagnose or track these eye diseases. The goal is to better understand what drives these conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better diagnostic tests or ways to predict how eye diseases will progress.
What could go wrong
This is an early-stage study focused on finding biomarkers, not testing a treatment. It may not directly lead to new therapies or benefit participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 260 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Ability to understand the study procedures and provide written informed consent * Willingness and ability to comply with study procedures and visits For case subjects: * Patients with age-related macular degeneration (intermediate or advanced, including geographic atrophy or neovascular AMD) * Patients with diabetic retinopathy (non-proliferative or proliferative, with or without diabetic macular edema) * Patients undergoing surgery for primary or recurrent retinal detachment For control subjects: * Patients scheduled for cataract surgery with no documented retinal diseases (e.g., AMD, diabetic retinopathy, retinal vascular occlusions, or retinal epithelial disorders) * Outpatients with no documented retinal diseases * For retinal detachment subgroup: patients undergoing macular surgery (e.g., macular pucker or macular hole) or cataract surgery with attached retina Exclusion Criteria: * Age \< 18 years * Presence of infectious ocular diseases * Alterations in the electrophoretic profile of gamma globulins

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related macular degeneration (AMD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration diabetic retinopathy macular degeneration retinal detachment

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age-related macular degeneration (AMD) Diabetic retinopathy (DR) Retinal detachment

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IRCCS Fondazione G.B.Bietti

    RECRUITING

    Roma, Italy, 00184, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.